Waves of SARS-CoV-2 Infection and Blood Coagulation—A Link and Beyond

Harenberg, Job; Violi, Francesco

doi:10.1055/s-0040-1721778

Cited by 4 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7% of inpatients treated with thromboembolism prophylaxis. 2 Several possible pathomechanisms have been discussed, including a direct endothelial damage 3 as well as an antibody-mediated activation of platelets via the Fcγ-IIa receptor. 4 Men are at an increased risk of a severe course of Covid-19 5 ; TE are presumably part of this multifactorial, gender-specific risk.…”

Section: Discussionmentioning

confidence: 99%

“…7% of inpatients treated with thromboembolism prophylaxis 2 . Several possible pathomechanisms have been discussed, including a direct endothelial damage 3…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…1,2 , Hohenstein S. 2 , Bollmann A. 2 , Bonsignore, M. 3 , Husser, D. 2 , Kuhlen R. 4 ; Meier-Hellmann A. 5 1 Helios Kliniken Ost and Klinikum Emil-von-Behring, irit.nachtigall@helios-gesundheit.de Over a year ago, the WHO declared COVID-19 a pandemic; from then on, all hopes were on the development of vaccines.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Thrombembolic Events in Hospitalized COVID-19 Patients: What is the Role of the Sex?

Nachtigall

Hohenstein

Bollmann

et al. 2021

TH Open

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…7% of inpatients treated with thromboembolism prophylaxis 2 . Several possible pathomechanisms have been discussed, including a direct endothelial damage 3…”

Section: Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Thrombembolic Events in Hospitalized COVID-19 Patients: What is the Role of the Sex?

Nachtigall

Hohenstein

Bollmann

et al. 2021

TH Open

View full text Add to dashboard Cite

show abstract

“…In acute COVID-19, the high risk of venous and arterial thrombosis prompted immediate use of ACs, 70 essentially low-molecular-weight heparin (LMWH), whose knowledge of functions in plasma, on cell surfaces, and on receptors is expanding. This increases the spectrum of medical therapies and therapeutic indications that heparin can offer, thus, promising approaches for the treatment of COVID-19 may also focus on heparin's non-AC effects.…”

Section: Therapeutic Approaches Acute Covid-19mentioning

confidence: 99%

COVID-19 and Long-COVID Thrombosis: From Clinical and Basic Science to Therapeutics

Violi,

Harenberg,

Pignatelli

et al. 2023

Thromb Haemost

Self Cite

View full text Add to dashboard Cite

Coronavirus infectious disease-19 (COVID-19) is a pandemic characterized by serious lung disease and thrombotic events in the venous and circulation trees, which represent a harmful clinical sign of poor outcome. Thrombotic events are more frequent in patients with severe disease requiring intensive care units and are associated with platelet and clotting activation. However, after resolution of acute infection, patients may still have clinical sequelae, the so-called long-COVID-19, including thrombotic events again in the venous and arterial circulation. The mechanisms accounting for thrombosis in acute and long COVID-19 have not been fully clarified; interactions of COVID-19 with angiotensin converting enzyme 2 or toll-like receptor family or infection-induced cytokine storm have been suggested to be implicated in endothelial cells, leucocytes, and platelets to elicit clotting activation in acute as well in chronic phase of the disease. In acute COVID-19, prophylactic or full doses of anticoagulants exert beneficial effects even if the dosage choice is still under investigation; however, a residual risk still remains suggesting a need for a more appropriate therapeutic approach. In long COVID-19 preliminary data provided useful information in terms of antiplatelet treatment but definition of candidates for thrombotic prophylaxis is still undefined.

show abstract